| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SAN DIEGO–Novasite Pharmaceuticals Inc. announced it has received a four-year grant valued at nearly $3.4 million for continued development of its proprietary parallel screening technology for G-Protein Coupled Receptors (GPCRs). The company's screening platform performs functional screens for allosteric modulators, a subclass of GPCR drugs the company contends can potentially have safer therapeutic action.
 
"The grant to continue development of our crystallography method of parallel screening of allosteric modulators is important in the development of Novasite for two reasons," says Kathryn Rucker, vice president corporate finance and development. "First it helps us preserve our capital to deploy in other ways and it allows us to increase our parallel screening using our proprietrary technology from 30 to more than 100 GPCRs."
 
The benefit of the parallel screening is in line with the continuing industry trend of "more and faster" and in this case allows for the screening of GPCR families, as opposed to other approaches that screen one receptor at a time. According to John Ransom, Ph.D. and vice president of biology at Novasite, the company's proprietary platform "is capable of detecting allosteric modulators, because it can reliably measure subtle variations in the signal induced by the natural ligand." By understanding these subtleties more completely, researchers can, in theory, create compounds that more selectively target single receptors as opposed to a whole family of receptors.
 
The intent for Novasite is to screen target libraries of other companies and organizations, but also to develop its own collection of potential drug candidates.

About the Author

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue